Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Dorzolamide hydrochloride and timolol maleate

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Dorzolamide hydrochloride and timolol maleate key facts

Used for
COSOPT® PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$0.9161 per mL (dorzolamide hydrochloride 20 mg/mL · timolol maleate 5 mg/mL; NADAC)
Latest FDA recall
July 22, 2026 (Class II)

Sources: FDA label (May 13, 2026); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Dorzolamide hydrochloride and timolol maleate used for?
The FDA-approved label (Cosopt Pf, Thea Pharma Inc., May 13, 2026) says: “COSOPT® PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Dorzolamide hydrochloride and timolol maleate?
The “Adverse Reactions” section of the FDA label (Cosopt Pf, Thea Pharma Inc., May 13, 2026) begins: “The most frequently reported adverse reactions were taste perversion (bitter, sour, or unusual taste) or ocular burning and/or stinging in up to 30% of patients. Conjunctival hyperemia, blurred vision, superficial punctate keratitis or eye itching were reported between 5-15% of patients.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Dorzolamide hydrochloride and timolol maleate?
The “Drug Interactions” section of the FDA label (Cosopt Pf, Thea Pharma Inc., May 13, 2026) begins: “Potential additive effect of oral carbonic anhydrase inhibitor with COSOPT PF. (7.1) Potential acid-base and electrolyte disturbances. (7.2) Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. (7.3) Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (7.4) Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Dorzolamide hydrochloride and timolol maleate have a boxed warning?
No. None of the 22 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Dorzolamide hydrochloride and timolol maleate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Dorzolamide hydrochloride and timolol maleate been recalled?
FDA enforcement reports list 1 recall of products of this medicine; the newest started July 22, 2026 (Class II). A recall usually concerns specific lots, not every product.
Who makes Dorzolamide hydrochloride and timolol maleate?
16 companies list prescription products of Dorzolamide hydrochloride and timolol maleate in the FDA NDC Directory, including Bryant Ranch Prepack, Micro Labs Limited and Thea Pharma Inc.

What Dorzolamide hydrochloride and timolol maleate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

COSOPT® PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). …

— FDA label: Cosopt Pf, Thea Pharma Inc., effective May 13, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (solution/ drops, ophthalmic), Cosopt Pf, Thea Pharma Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 22 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 22 FDA labels for this medicine have a boxed warning.

Dorzolamide hydrochloride and timolol maleate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The most frequently reported adverse reactions were taste perversion (bitter, sour, or unusual taste) or ocular burning and/or stinging in up to 30% of patients. Conjunctival hyperemia, blurred vision, superficial punctate keratitis or eye itching were reported between 5-15% of patients.

Read more of this section

(6) To report SUSPECTED ADVERSE REACTIONS, contact Thea Pharma Inc. at 1-833-838-4028 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. COSOPT and COSOPT PF COSOPT and COSOPT PF were evaluated in patients with elevated intraocular pressure treated for open-angle glaucoma or ocular hypertension for up to 15 months. Approximately 5% of all patients discontinued therapy because of adverse reactions. The most frequently reported adverse reactions occurring in up to 30% of patients were taste perversion (bitter, sour, or unusual taste) or ocular burning and/or stinging. The following adverse reactions were reported in 5% to 15% of patients: conjunctival hyperemia, blurred vision, superficial punctate keratitis or eye itching. The following adverse reactions were reported in 1% to 5% of patients: abdominal pain, back pain, blepharitis, bronchitis, cloudy vision, conjunctival discharge, conjunctival edema, conjunctival follicles, conjunctival injection, conjunctivitis, corneal erosion, corneal staining, cortical lens opacity, cough, dizziness, dryness of eyes, dyspepsia, eye debris, eye discharge, eye pain, eye tearing, eyelid edema, eyelid erythema, eyelid exudate/scales, eyelid pain or discomfort, foreign body sensation, glaucomatous cupping, headache, hypertension, influenza, lens nucleus coloration, lens opacity, nausea, nuclear lens opacity, pharyngitis, post-subcapsular cataract, sinusitis, upper respiratory infection, urinary tract infection, visual field defect, vitreous detachment. Other adverse reactions that have been reported with the individual components are listed below: Dorzolamide 2% Angioedema, asthenia/fatigue, bronchospasm, contact dermatitis, epistaxis, eyelid crusting, ocular discomfort, photophobia, signs and symptoms of ocular allergic reaction, transient myopia.

— FDA label: Cosopt Pf, Thea Pharma Inc., effective May 13, 2026. This is part of the section. Read the full label on DailyMed →

Dorzolamide hydrochloride and timolol maleate drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Potential additive effect of oral carbonic anhydrase inhibitor with COSOPT PF. (7.1) Potential acid-base and electrolyte disturbances. (7.2) Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. (7.3) Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (7.4) Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia.

Read more of this section

(7.5) Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (7.6) CYP2D6 inhibitors may potentiate systemic beta-blockade. (7.7) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and COSOPT PF. The concomitant administration of COSOPT PF and oral carbonic anhydrase inhibitors is not recommended. 7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving COSOPT PF. 7.3 Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and COSOPT PF should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. 7.4 Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as COSOPT PF, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, coadministration should be avoided. 7.5 Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. 7.6 Digitalis and Calcium Antagonists The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. 7.7 CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. 7.8 Clonidine Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. There have been no reports of exacerbation of rebound hypertension with ophthalmic timolol maleate.

— FDA label: Cosopt Pf, Thea Pharma Inc., effective May 13, 2026. Read the full label on DailyMed →

Dorzolamide hydrochloride and timolol maleate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

The dose is one drop of COSOPT PF in the affected eye(s) two times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart [see Drug Interactions (7.3)]. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes.

Read more of this section

Since sterility cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration. The dose is one drop of COSOPT PF in the affected eye(s) two times daily. (2)

— FDA label: Cosopt Pf, Thea Pharma Inc., effective May 13, 2026. Read the full label on DailyMed →

Dorzolamide hydrochloride and timolol maleate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary There are no adequate and well-controlled studies of COSOPT PF in pregnant women to inform a drug-associated risk. No evidence of teratogenicity has been observed in mice, rat, and rabbits with dorzolamide hydrochloride or timolol at clinically relevant doses [see Data].

Read more of this section

Data Animal Data Oral administration of dorzolamide hydrochloride in pregnant rabbits at oral doses of ≥2.5 mg/kg/day (31 times the recommended human ophthalmic dose) revealed malformations of the vertebral bodies. These malformations occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased fetal weights. No treatment-related malformations were seen at 1 mg/kg/day (13 times the recommended human ophthalmic dose). Oral administration of timolol in pregnant mice, rats and rabbits at does up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1,000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.

— FDA label: Cosopt Pf, Thea Pharma Inc., effective May 13, 2026. Read the full label on DailyMed →

When Dorzolamide hydrochloride and timolol maleate should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

COSOPT PF is contraindicated in patients with: Bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease. (4.1) Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock. (4.2) Hypersensitivity to any component of this product.

Read more of this section

(4.3, 5.3) 4.1 Asthma, COPD COSOPT PF is contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease [see Warnings and Precautions (5.1)]. 4.2 Sinus Bradycardia, AV Block, Cardiac Failure, Cardiogenic Shock COSOPT PF is contraindicated in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock [see Warnings and Precautions (5.2)]. 4.3 Hypersensitivity COSOPT PF is contraindicated in patients who are hypersensitive to any component of this product [see Warnings and Precautions (5.3)].

— FDA label: Cosopt Pf, Thea Pharma Inc., effective May 13, 2026. Read the full label on DailyMed →

Dorzolamide hydrochloride and timolol maleate overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

Symptoms consistent with systemic administration of beta-blockers or carbonic anhydrase inhibitors may occur, including electrolyte imbalance, development of an acidotic state, dizziness, headache, shortness of breath, bradycardia, bronchospasm, cardiac arrest and possible central nervous system effects. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.

Read more of this section

[See Adverse Reactions (6).] A study of patients with renal failure showed that timolol did not dialyze readily.

— FDA label: Cosopt Pf, Thea Pharma Inc., effective May 13, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsSolution/ drops · Solution
RouteOphthalmic
Prescription products22 in the FDA NDC Directory
Brand namesCosopt Pf, Cosopt, Dorzolamide Hydrochloride Timolol Maletae

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Dorzolamide hydrochloride and timolol maleate, by strength and form
Strength and formGeneric or brandPharmacies pay
dorzolamide hydrochloride 20 mg/mL · timolol maleate 5 mg/mL
solution
Generic $0.9161 per mL
dorzolamide hydrochloride 20 mg/mL · timolol maleate 5 mg/mL
solution/ drops
Generic $1.01 per unit
dorzolamide hydrochloride 20 mg/mL · timolol maleate 5 mg/mL
solution/ drops
Generic $0.9161 per mL
dorzolamide hydrochloride 20 mg/mL · timolol maleate 5 mg/mL
solution/ drops
Brand: Cosopt $23.17 per mL
dorzolamide hydrochloride 20 mg/mL · timolol maleate 5 mg/mL
solution/ drops
Brand: Cosopt Pf $3.30 per unit
dorzolamide hydrochloride 22.3 mg/mL · timolol maleate 6.8 mg/mL
solution/ drops
Generic $0.9161 per mL

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA020869
COSOPT
Thea PharmaApril 7, 1998 22, latest November 23, 2020
2020: Labeling · 2015: Labeling · 2010: Labeling
NDA202667
COSOPT PF
Thea PharmaFebruary 1, 2012 1, latest April 9, 2026
2026: Labeling

Generic approvals (12)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.

  1. July 22, 2026 · Class II · Ongoing · D-0730-2026

    Defective Container: Firm received multiple complaints of broken cap spikes and undeliverable drops.

    Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, USP, 2%/0.5%, 10mL - bottle, Rx only, Manufactured by: Micro Labs Limited, India, Manufactured for: Micro Labs USA Inc., Somerset, NJ 08873. NDC 42571-147-26. — MICRO LABS USA INC

What do the recall classes mean?

Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).

Official identifiers

RxCUI (RxNorm)1922783, 1922784, 1923432, 1923433
SPL set ID of the quoted label535fc801-8c3f-4974-a120-3eff1d5a5062
FDA labels (SPL)22
FDA applicationsNDA020869, NDA202667, 12 ANDA
Active ingredients (FDA)DORZOLAMIDE / TIMOLOL

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Cosopt Pf, Thea Pharma Inc., effective May 13, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers